Commercialization through a sales partnership with Shionogi & Co., Ltd. for an app to treat insomnia
First written in FY2022-Q2. 11 of 20 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026DroppedAnnual report
「As of the date of submission of this document, the sales partnership agreement has ended.」
It was stated that the sales partnership agreement with Shionogi & Co., Ltd. for the insomnia disorder app had ended. - FY2026-H1RestatedAnnual report
「Under the sales partnership agreement concluded with Shionogi & Co.,Ltd. for the App, we expect to receive milestone payments totaling up to ¥4.1 billion based on development progress and other factors, as well as royalties based on sales after the product launch.」
The framework of milestone revenue of up to ¥4.1 billion and royalties after product launch under the sales partnership with Shionogi continues. - FY2025-H1RestatedAnnual report
「Going forward, under the sales partnership agreement for the Application with Shionogi & Co., Ltd., the Company expects to receive milestone payments totaling up to ¥4.1 billion depending on future development progress, as well as royalties based on sales after the product launch.」
The framework of milestone revenue of up to ¥4.1 billion and royalties after launch under the sales partnership with Shionogi continues. - FY2024-Q3RestatedAnnual report
「Going forward, under the sales partnership agreement for the Application with Shionogi & Co., Ltd., the Company expects to receive milestone payments totaling up to ¥4.1 billion depending on future development progress, as well as royalties based on sales after the product launch.」
The framework of milestone revenue of up to ¥4.1 billion and royalties after launch under the sales partnership with Shionogi continues. - FY2024-Q2RestatedAnnual report
「Going forward, under the sales partnership agreement for the Application with Shionogi & Co., Ltd., the Company expects to receive milestone payments totaling up to ¥4.1 billion depending on future development progress, as well as royalties based on sales after the product launch.」
The framework of milestone revenue of up to ¥4.1 billion and royalties after launch under the sales partnership with Shionogi continues. - FY2024-Q1RestatedAnnual report
「Going forward, under the sales partnership agreement for the Application with Shionogi & Co., Ltd., the Company expects to receive milestone payments totaling up to ¥4.1 billion depending on future development progress, as well as royalties based on sales after the product launch.」
The framework of milestone revenue of up to ¥4.1 billion and royalties after launch under the sales partnership with Shionogi continues. - FY2023RestatedAnnual report
「Following receipt of marketing authorization as a medical device, the Company received a ¥400 million milestone payment under the sales partnership agreement for the Application with Shionogi & Co., Ltd. Going forward, it expects to receive additional milestone payments totaling up to ¥4.1 billion depending on future development progress and royalties based on sales after the product launch.」
The disclosure describes the receipt of a ¥400 million milestone payment upon obtaining approval and the framework of future milestone payments of up to ¥4.1 billion and royalties after launch. - FY2023-Q3AdvancedAnnual report
「Under the sales partnership agreement for the Application with Shionogi & Co., Ltd., the Company received a ¥400 million milestone payment related to marketing authorization as a medical device. Going forward, it expects to receive additional milestone payments totaling up to ¥4.1 billion depending on future development progress and other factors, as well as royalties based on sales after the product launch.」
The Company received a ¥400 million milestone payment upon obtaining approval. Meanwhile, the cap on total future milestone payments has changed from the previous ¥4.5 billion to ¥4.1 billion. - FY2023-Q2RestatedAnnual report
「Under the sales partnership agreement for the Application with Shionogi & Co., Ltd., the Company expects to receive milestone payments totaling up to ¥4.5 billion depending on future development progress and other factors, as well as royalties based on sales after the product launch.」
The framework of the sales partnership with Shionogi, milestone revenue of up to ¥4.5 billion and royalties after launch continues. - FY2023-Q1RestatedAnnual report
「Under the agreement, the Company expects to receive milestone payments totaling up to ¥4.5 billion depending on future development progress and other factors, as well as royalties based on sales after the product launch.」
The framework of the sales partnership with Shionogi, milestone revenue of up to ¥4.5 billion and royalties after launch continues. - FY2022RestatedAnnual report
「The Company has received an upfront payment of ¥200 million from Shionogi & Co., Ltd. upon execution of the agreement and expects to receive additional milestone payments totaling up to ¥4.5 billion depending on future development progress and other factors. In addition to these milestone payments, the Company will receive royalties based on sales after the product launch.」
The framework of the sales partnership with Shionogi, the upfront payment, milestone payments of up to ¥4.5 billion and royalties after launch continues. - FY2022-Q3SoftenedAnnual report
「The Company has received an upfront payment of ¥200 million from Shionogi upon execution of the agreement and expects to receive additional milestone payments totaling up to ¥4.5 billion depending on future development progress and other factors. In addition to these milestone payments, the Company will receive royalties based on sales after the product launch.」
The framework of the sales partnership agreement, upfront payment and royalties continues, while the maximum milestone revenue has changed from the ¥4.7 billion previously disclosed to ¥4.5 billion. - FY2022-Q2AdvancedAnnual report
「In December, the Company entered into a sales partnership agreement for the Application with Shionogi & Co., Ltd. (headquartered in Chuo-ku, Osaka; hereinafter “Shionogi”). Under the agreement, the Company, as the marketing authorization holder for the Application, will proceed with its development and preparations for regulatory approval and reimbursement, while Shionogi will acquire exclusive sales rights for the Application in Japan. In addition to an upfront payment received from Shionogi upon execution of the agreement, the Company will receive milestone payments totaling up to ¥4.7 billion depending on future development progress and other factors, as well as royalties based on sales after the product launch.」
The Company entered into the sales partnership agreement in December 2021 and recognized an upfront payment of ¥200 million. The agreement remains in effect until the date on which 10 years have elapsed from the launch date of the Application.